Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Chlamydia pneumoniae activates IKK/I kappa B-mediated signaling, which is inhibited by 4-HNE and following primary exposure.

Donath B, Fischer C, Page S, Prebeck S, Jilg N, Weber M, da Costa C, Neumeier D, Miethke T, Brand K.

Atherosclerosis. 2002 Nov;165(1):79-88.

PMID:
12208473
2.

4-Hydroxynonenal prevents NF-kappaB activation and tumor necrosis factor expression by inhibiting IkappaB phosphorylation and subsequent proteolysis.

Page S, Fischer C, Baumgartner B, Haas M, Kreusel U, Loidl G, Hayn M, Ziegler-Heitbrock HW, Neumeier D, Brand K.

J Biol Chem. 1999 Apr 23;274(17):11611-8.

3.

Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacterial development in human endothelial cells.

Tiran A, Gruber HJ, Graier WF, Wagner AH, Van Leeuwen EB, Tiran B.

Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1075-80.

PMID:
12117719
5.

Contact of Chlamydophila pneumoniae with type II cell triggers activation of calcium-mediated NF-kappa B pathway.

Wissel H, Müller T, Rüdiger M, Krüll M, Wauer RR.

Biochim Biophys Acta. 2005 Mar 22;1743(1-2):37-48.

7.
8.

A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts.

Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huynh K, Bonar S, Mielke C, Albee L, Weier R, Graneto M, Hanau C, Perry T, Tripp CS.

J Biol Chem. 2003 Aug 29;278(35):32861-71. Epub 2003 Jun 17.

9.

Mechanisms of Chlamydophila pneumoniae-mediated GM-CSF release in human bronchial epithelial cells.

Krüll M, Bockstaller P, Wuppermann FN, Klucken AC, Mühling J, Schmeck B, Seybold J, Walter C, Maass M, Rosseau S, Hegemann JH, Suttorp N, Hippenstiel S.

Am J Respir Cell Mol Biol. 2006 Mar;34(3):375-82. Epub 2005 Dec 9.

PMID:
16340003
10.

Survival of Chlamydia pneumoniae-infected Mono Mac 6 cells is dependent on NF-kappaB binding activity.

Wahl C, Oswald F, Simnacher U, Weiss S, Marre R, Essig A.

Infect Immun. 2001 Nov;69(11):7039-45.

11.

4-hydroxynonenal induces apoptosis, NF-kappaB-activation and formation of 8-isoprostane in vascular smooth muscle cells.

Ruef J, Moser M, Bode C, Kübler W, Runge MS.

Basic Res Cardiol. 2001 Apr;96(2):143-50.

PMID:
11327332
12.
14.

A20 inhibits NF-kappa B activation downstream of multiple Map3 kinases and interacts with the I kappa B signalosome.

Zetoune FS, Murthy AR, Shao Z, Hlaing T, Zeidler MG, Li Y, Vincenz C.

Cytokine. 2001 Sep 21;15(6):282-98.

PMID:
11594795
15.

Aspirin inhibits Chlamydia pneumoniae-induced NF-kappa B activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth.

Yoneda H, Miura K, Matsushima H, Sugi K, Murakami T, Ouchi K, Yamashita K, Itoh H, Nakazawa T, Suzuki M, Shirai M.

J Med Microbiol. 2003 May;52(Pt 5):409-15.

PMID:
12721317
17.

Role of IRAK4 and IRF3 in the control of intracellular infection with Chlamydia pneumoniae.

Trumstedt C, Eriksson E, Lundberg AM, Yang TB, Yan ZQ, Wigzell H, Rottenberg ME.

J Leukoc Biol. 2007 Jun;81(6):1591-8. Epub 2007 Mar 14.

PMID:
17360955
18.

Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells.

Molestina RE, Miller RD, Lentsch AB, Ramirez JA, Summersgill JT.

Infect Immun. 2000 Jul;68(7):4282-8.

19.
20.

IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes.

Regula KM, Ens K, Kirshenbaum LA.

J Biol Chem. 2002 Oct 11;277(41):38676-82. Epub 2002 Aug 7.

Supplemental Content

Support Center